CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing round, securing USD 53 million in capital. This financing was co-led by TVM Capital Life Science and China-focused Yonjin Ventures, with significant participation from existing investors including SV Health Investors, Ascension Ventures, First Analysis, Blue Heron, and Intersouth Partners.
The capital raised will be instrumental in supporting the company through the anticipated U.S. Food and Drug Administration (FDA) premarket approval (PMA) process and the commercialization efforts for its flagship product, The RejuvenAir System. This innovative system utilizes liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis, offering a potential new therapeutic approach in the respiratory healthcare sector. – Flcube.com
